Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Sep 5, 2012
Ajay Kirtane, MD, SM, FSCAI, and SCAI President J. Jeffrey Marshall, MD, FSCAI discuss the FAME 2 trial, in which FFR was performed on every patient to confirm that "hemodynamically significant" (or "tight") blockages in their coronary arteries were limiting blood flow. The patients with hemodynamically significant blockages were then randomized to PCI plus the best medications available or medications alone.